Thesis Care Rebrands and Raises $45 Million to Expand AI-Powered Clinical Teams
Thesis Care, the healthcare AI company formerly known as Trovo Health, has announced a $45 million Series A round led by Oak HC/FT, with participation from CRV, Black Opal Ventures, and healthcare technology angel investors. The new financing brings the company’s total funding to $60 million and arrives alongside a rebrand that signals a broader push into scalable clinical operations for healthcare organizations. The timing feels deliberate, almost like a reset moment as the company moves from early validation into something closer to full-scale deployment.
The company’s positioning is pretty clear once you look past the usual AI language. Thesis Care is not trying to sell another tool that sits on top of existing systems. Instead, it frames itself as a working layer inside healthcare operations, deploying AI agents alongside real clinicians to handle care management and administrative workflows end to end. That distinction matters more than it sounds, because healthcare organizations are already overloaded with platforms that promise efficiency but ultimately add friction.
At the core of the platform is AI designed to understand clinical context and act on it, not just analyze it. It handles patient engagement, executes workflow steps, and escalates to human experts when needed. That human-in-the-loop element is central to how Thesis positions itself. The pitch is not automation replacing people, but automation extending clinical capacity in a way that still preserves judgment where it counts. In practice, that likely means fewer dropped tasks, fewer missed follow-ups, and a more consistent handling of routine but critical care processes.
The company says its partnerships already span thousands of providers, including large organizations across primary and specialty care such as U.S. Heart & Vascular, Essen Health Care, Springfield Clinic, Unio Health Partners, and Allied Digestive Health. There is also a clear move toward working with health systems and health plan care teams, which hints at a broader ambition. This is not just about supporting individual practices; it is about embedding into the larger infrastructure of care delivery.
What stands out in the customer feedback is how operational the benefits sound. Reduced administrative burden, faster deployment, better-prepared patients, and measurable ROI. Nothing abstract there. That tone tends to show up when a system is already doing real work rather than being piloted in controlled environments. Healthcare buyers, especially at scale, tend to filter out anything that cannot translate into those kinds of outcomes.
With the new funding, Thesis Care plans to accelerate its commercial expansion, deepen its unified platform, and expand the range of care team agents it offers. That suggests a roadmap focused on both horizontal growth across more organizations and vertical depth within existing workflows. If they can execute on both at once, that is where these platforms start to feel less like vendors and more like infrastructure.
The rebrand from Trovo Health to Thesis Care also feels like part of that shift. The new name carries a more structured, almost foundational tone, which aligns with how the company wants to be perceived. In enterprise healthcare, perception and positioning often shape adoption as much as technical capability.
Stepping back a bit, this funding round fits into a larger pattern across healthcare AI. The early wave focused heavily on copilots and decision support. The next wave, which Thesis Care is leaning into, is about actually completing work inside clinical and operational systems. That shift from insight to execution might end up being the real dividing line between experiments and lasting adoption.
If that direction holds, companies that combine AI with embedded human expertise could end up defining the category. Pure automation struggles with edge cases and trust, while purely human systems struggle with scale. The hybrid model sits in between, and right now, it looks like one of the more realistic paths forward.